Tiziana Life Sciences plc (TLSA) NPV

Sell:$1.95Buy:$1.98$0.01 (0.51%)

Prices delayed by at least 15 minutes
Sell:$1.95
Buy:$1.98
Change:$0.01 (0.51%)
Prices delayed by at least 15 minutes
Sell:$1.95
Buy:$1.98
Change:$0.01 (0.51%)
Prices delayed by at least 15 minutes

Company Information

About this company

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).

Key people

Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Ivor Elrifi
Chief Executive Officer, Executive Director
Keeren Shah
Chief Financial Officer, Chief Operating Officer
William A. Clementi
Chief Development Officer
John P. Brancaccio
Non-Executive Independent Director
Willy Jules Simon
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    TLSA
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    BMG889121031
  • Market cap
    $217.35m
  • Employees
    8
  • Shares in issue
    111.46m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.